Pfizer, which had the vaccine furthest along in testing, doesn’t plan to seek FDA emergency use authorization until late Nov. https://t.co/RjiKXNfXsH

— Shannon Pettypiece (@spettypi) October 16, 2020

Pfizer won't seek coronavirus vaccine authorization until after election https://t.co/YVbAV1qQyC

— Paul Duprex (@10queues) October 16, 2020

화이자가 개발중인 코로나19 백신이 빠르면 11월 말에 긴급사용승인을 신청할 수 있을 전망. https://t.co/E5bChExTHn

— 푸른곰 (@purengom) October 16, 2020

Pfizer to seek FDA approval for Covid -19 vaccine in November https://t.co/qDyN3uDfWG

— Financial Times (@FT) October 16, 2020

Pfizer to seek FDA approval for Covid -19 vaccine in November

US group and German partner BioNTech prepare to submit trial results next month #CovidVaccine https://t.co/tKklKM1un3

— Justin Waite (@SharePickers) October 16, 2020

Pfizer to seek FDA approval for Covid -19 vaccine in November | Financial Times$PFE $BNTX https://t.co/WfmmzY0xiY

— zach (@zbiotech) October 16, 2020

ファイザーのCEOは、同社が11月下旬までにコロナウイルスワクチンの米国緊急使用承認を申請できると述べています。https://t.co/mgSNAGS6UK

大丈夫?　　前のめりすぎない？
(・_・;) https://t.co/ShbmLNMfUu

— きままねこ (@sekainokinoneko) October 16, 2020

◆11月下旬に申請へ
・ファイザーがビオンテックと共同治験中のコロナワクチンを11月下旬に緊急使用許可を申請する考え
・WSJなどが報道
・これまで副作用は目立たず、11月3週に安全性確認も
・ファイザー株は1%高
・他企業では抗体薬などで治験を一時中断する動きも

▽WSJhttps://t.co/7mF1m1QqHg

— 後藤達也（日本経済新聞） (@goto_nikkei) October 16, 2020

We provided an update on the potential timelines for the #COVID19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. https://t.co/62njuhX3lu

— BioNTech SE (@BioNTech_Group) October 16, 2020

Pfizer may apply for emergency use of COVID-19 vaccine by late November | Fox Business https://t.co/KSoChySPm7

— David, Ph.D. (@americanshomer) October 16, 2020

Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November - WSJ https://t.co/m2ekolsaiF

— Soumyajit Pattnaik (@soumyajitt) October 16, 2020

“Pfizer, and German part­ner Bio­NTech, ex­pects to have data on vaccine candidate’s ef­fec­tive­ness - whether it pro­tects most vac­ci­nated peo­ple from #Covid19 - later this month. It ex­pects to have data on drug’s safety by third week of No­vember.” https://t.co/CWpZ2djtkn

— Rick Anderson ?? (@RickAnderson) October 16, 2020

Pfizer said it could be ready to apply for emergency-use authorization of its Covid-19 vaccine by late November https://t.co/Dicuuky7rE

— Jesus Alvelo (@MinistroCiencia) October 16, 2020